A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Who can join: the full rules

Inclusion Criteria:

* Biopsy proven cutaneous squamous cell carcinoma which is locally advanced

  * Mixed histology tumors that are predominantly squamous cell carcinoma are eligible
  * Locally advanced primary tumor is T3-T4 and/or N+ by AJCC and/or UICC 8th edition clinical criteria
* T3-T4 primary tumor characteristics noted below:

  * Non-eyelid tumor \>4 cm in maximum dimension or with bone erosion or invasion, perineural invasion of nerve 0.1 mm or larger, or invasion beyond subcutaneous fat or \>6 mm from granular layer of adjacent normal epidermis
  * Eyelid tumor \>2 cm or invading adjacent ocular, orbital or facial structures
* ≥18 years old
* Unresectable or medically inoperable according to local multidisciplinary consensus for reasons such as:

  * Tumor or regional lymph node metastases that has recurred despite ≥2 prior surgical procedures, with another curative resection unlikely
  * Tumor or nodal disease with significant local invasion that precludes complete resection
  * Tumor or nodal disease in anatomically challenging area where surgery may result in significant disfigurement or dysfunction (amputation of nose, ear, eye, digit, limb, etc)
  * Medical contraindication to surgery
  * Patient refusal of surgery due to anticipate morbidity
* ECOG ≤2
* Adequate bone marrow and metabolic function (by blood tests)

  * Total bilirubin ≤1.5 x upper limit of normal
  * Aspirate aminotransferase (AST) ≤3 x upper limit of normal
  * Alanine aminotransferase (ALT) ≤3 x upper limit of normal
  * Alkaline phosphatase ≤2.5 x upper limit of normal
  * Serum creatinine ≤1.5 x upper limit of normal or estimated creatinine clearance \>30 mL/min according to Cockcroft-Gault formula
  * Hemoglobin \>9 g/dL
  * Absolute neutrophil count ≥1.5 x10\^9/L
  * Platelet count ≥75 x10\^9/L
* Able to provide informed consent
* Acceptable candidate for curative intent radiotherapy and Cemiplimab immunotherapy, in opinion of radiation and medical oncologist, respectively
* Life expectancy \>18 months

Exclusion Criteria:

* Primary tumor originating on the mucosal (non-hair bearing) lip or nose, anogenital (penis, scrotum, vulva, perianal) area
* Iatrogenic immunosuppression (\>prednisone 10 mg/day or equivalent within 14 days of initiation of treatment)
* Women of child bearing potential unwilling or unable to use effective contraception while receiving treatment with cemiplimab and for 4 months thereafter
* Distant metastases
* Clinically significant autoimmune disease that requires iatrogenic immunosuppression

  o For example, severe rheumatoid arthritis requiring disease modifying antirheumatic drugs, such as methotrexate
* Current or previous hematopoietic malignancy (leukemia, lymphoma)
* Prior allogeneic transplant of solid organ or bone marrow
* Concurrent malignancies with \>10% risk of metastasis or death within 2 years
* Prior aPD1 immunotherapy or PI3Kδ inhibitor use
* Prior radiotherapy for the cutaneous squamous cell carcinoma requiring treatment
* Other ongoing cancer therapy

  o Adjuvant endocrine therapy is permitted for patients with prostate or breast cancer
* Uncontrolled HIV or infectious hepatitis (viral load detectable in patient with known infection)
* Pregnancy or breastfeeding
* Comorbid or diagnostic abnormalities within the last year that would interfere with interpretation of study results

Where it's running

• University of Colorado (Data Collection Only)
  Aurora, Colorado, United States
• Moffitt Cancer Center (Data Collection Only)
  Tampa, Florida, United States
• Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities)
  Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Monmouth (All Protocol Activities)
  Middletown, New Jersey, United States
• Memorial Sloan Kettering Bergen (All protocol activities)
  Montvale, New Jersey, United States
• Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
  Commack, New York, United States

Study contacts

• Principal investigator: Christopher Barker, MD — Memorial Sloan Kettering Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Combining gemcitabine, cisplatin, nab-paclitaxel and cemiplimab to shrink locally advanced biliary tract cancer

  This trial will try whether giving gemcitabine, cisplatin, nab-paclitaxel plus cemiplimab can shrink previously inoperable biliary tract cancers so surgery becomes possible.

  Recruiting Phase 2 Columbia University · New York, New York · NCT07433673

• Neoadjuvant Cemiplimab for Merkel Cell Carcinoma in Stage I–II

  This study tests whether giving Cemiplimab before surgery helps people with early-stage Merkel cell carcinoma see if tumors shrink or disappear before sentinel node biopsy.

  Recruiting at 11 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Heidelberg, Baden-Wurttemberg and 11 other locations · NCT07387198

• Capecitabine/Oxaliplatin chemo with cemiplimab with or without fianlimab or REGN7075 for locally advanced rectal cancer

  This trial tests whether adding cemiplimab, cemiplimab with fianlimab, or cemiplimab with REGN7075 to CAPOX can help people with MSS locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07281768

• Adding cemiplimab to chemotherapy before surgery for sinonasal squamous cell carcinoma

  This test checks whether adding the immunotherapy cemiplimab to carboplatin and paclitaxel before surgery helps people with locally advanced sinonasal squamous cell carcinoma.

  Recruiting at 18 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 17 other locations · NCT07281417

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.